Field | Sense | Antisense |
siRNA chemical modification | Palmitic acid* 2-Deoxyribonucleotide* Inverted thymidine | 2-Deoxyribonucleotide* Inverted thymidine |
siRNA modification types | 3 | 2 |
Overall number of modifications | 3 | 2 |
Position of modifications | 1 * 20 * 21 | 20 * 21 |
Modification on sugar or base or phosphate | Phosphate; Sugar; Sugar | Sugar |
SMILES (Click to view structure & nomenclature) |
CCCCCCCCCCCCCCCC(=O)NCCCCCCO OCC1OCCC1O CC1=CN(C2CC(OP([O-])(=O)OC3CCOC3CO)C(CO)O2)C(=O)NC1=O |
OCC1OCCC1O CC1=CN(C2CC(OP([O-])(=O)OC3C(O)COC3CO)C(CO)O2)C(=O)NC1=O |
siRNA Sequence | UCCUACAGCACAACAAAUGUG | CAUUUGUUGUGCUGUAGGAAG |
siRNA length base-pair | 21 | 21 |
siRNA name in paper | C16-siVEGF-idT | C16-siVEGF-idT |
Biological activity | 4 percent target mRNA inhibition | |
Experiment used to check activity | Real-time PCR | |
Melting temperature (oC) | NA | |
Target gene | vascular endothelial growth factor (VEGF) gene | |
siRNA concentration | 1 uM | |
Cell or Organism used | HeLa cells | |
Transfection method | Absence of Lipofectamine 2000 | |
Duration after transfection | 120 Hours | |
Article title | Palmitic acid-conjugated 21-nucleotide siRNA enhances gene-silencing activity |
|
Reference | 21985606 |